Table 3.
Gemcitabine and dFdU population pharmacokinetic parameter estimates
| Parameter* | Estimates | BSV (CV%) | BOV (CV%) |
|---|---|---|---|
| Qgem (l min−1) | 0.7 | 44 | – |
| CLgem (l min−1) | 2.7 | 31 | 12 |
| VC,gem (l) | 15 | 39 | 93 |
| VP,gem (l) | 15 | 64 | – |
| QdFdU/F (l min−1) | 0.2 | 29 | – |
| CLdFdU/F (l min−1) | 0.04 | 35 | 11 |
| VC,dFdU/F(l) | 46 | 15 | 10 |
| VP,dFdU/F(l) | 192 | 38 | – |
| Residual variability | σGEM | 40 | – |
| σdFdU | 19 | – |
*
The parameters described are intercompartmental clearance (Q), systemic clearance (CL) and the volume of distribution of the central (Vc) and peripheral (Vp) compartments for gemcitabine (subscript, gem) and its metabolite (subscript, dFdU). Note: apparent pharmacokinetic parameters are derived for dFdU as the fraction (F) of gemcitabine converted to this metabolite. F is not explicitly estimated. BSV, between-subject variability; BOV, between-occasion variability.